Alpha Tau Medical Ltd. - Warrant (NQ:DRTSW)

0.3000 -0.0191 (-5.99%)

Streaming Delayed Price Updated: 9:56 AM EST, Nov 25, 2025 Add to My Watchlist

Price and Volume

Volume	2,743
Open	0.3000
Bid (Size)	0.2800 (2,800)
Ask (Size)	0.3000 (3,600)
Prev. Close	0.3191
Today's Range	0.2966 - 0.3000
52wk Range	0.1425 - 0.5000
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

October 21, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

September 02, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Performance

YTD	+25.0%	+25.0%
1 Month	-23.1%	-23.1%
3 Month	+0.9%	+0.9%
6 Month	+20.0%	+20.0%
1 Year	+57.9%	+57.9%

More News

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

April 28, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

April 02, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

February 24, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease

February 03, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

January 27, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

December 18, 2024

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

December 17, 2024

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

October 21, 2024

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Treats First Patient with Recurrent Lung Cancer

October 10, 2024

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

September 20, 2024

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

June 25, 2024

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

May 13, 2024

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 20, 2023

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

November 28, 2023

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer

November 20, 2023

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility

October 30, 2023

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board

October 24, 2023

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel’s Hadassah Medical Center

September 14, 2023

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT

August 17, 2023

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University

May 17, 2023

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open

May 11, 2023

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial

April 03, 2023

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial

March 08, 2023

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Frequently Asked Questions

Is Alpha Tau Medical Ltd. - Warrant publicly traded?

Yes, Alpha Tau Medical Ltd. - Warrant is publicly traded.

What exchange does Alpha Tau Medical Ltd. - Warrant trade on?

Alpha Tau Medical Ltd. - Warrant trades on the Nasdaq Stock Market

What is the ticker symbol for Alpha Tau Medical Ltd. - Warrant?

The ticker symbol for Alpha Tau Medical Ltd. - Warrant is DRTSW on the Nasdaq Stock Market

What is the current price of Alpha Tau Medical Ltd. - Warrant?

The current price of Alpha Tau Medical Ltd. - Warrant is 0.3000

When was Alpha Tau Medical Ltd. - Warrant last traded?

The last trade of Alpha Tau Medical Ltd. - Warrant was at 11/25/25 09:56 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.